[Novel pharmaceutical treatment approaches for gastric cancer].

about

[Novel pharmaceutical treatment approaches for gastric cancer].

Item

http://www.wikidata.org/entity/Q53750080

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

[Novel pharmaceutical treatment approaches for gastric cancer].

@en

[Novel pharmaceutical treatment approaches for gastric cancer].

@nl

type

Item

label

[Novel pharmaceutical treatment approaches for gastric cancer].

@en

[Novel pharmaceutical treatment approaches for gastric cancer].

@nl

prefLabel

[Novel pharmaceutical treatment approaches for gastric cancer].

@en

[Novel pharmaceutical treatment approaches for gastric cancer].

@nl

P1476

[Novel pharmaceutical treatment approaches for gastric cancer].

@en

P2093

F Lordick

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Epidemiology of gastric cancer.

Clinical impact of tumour biology in the management of gastroesophageal cancer

Suppression of cancer relapse and metastasis by inhibiting cancer stemness

Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).

Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas.

P2888

s00292-017-0272-2

P304

87-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00292-017-0272-2

http://www.w3.org/2001/XMLSchema#string

P407

Af-Jarmal

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28220199

http://www.w3.org/2001/XMLSchema#string